Who Is Dr. Rita Bakshi?
Dr. Rita Bakshi is a board-certified maternal-fetal medicine (MFM) physician and Associate Professor of Obstetrics and Gynecology at the University of California, San Francisco (UCSF). She completed her obstetrics and gynecology residency at New York Presbyterian–Weill Cornell Medical Center and her MFM fellowship at UCSF, where she has practiced since 2012. With over 14 years of clinical experience and more than 85 peer-reviewed publications, Dr. Bakshi specializes in high-risk pregnancy management—particularly gestational diabetes mellitus (GDM), hypertensive disorders, and preterm birth prevention. Her work bridges rigorous clinical research with frontline care delivery, consistently emphasizing patient-centered decision-making, health equity, and protocol standardization grounded in real-world outcomes.
Unlike many specialists who focus solely on tertiary referral centers, Dr. Bakshi co-leads UCSF’s Perinatal Equity Initiative—a program launched in 2018 that reduced Black infant mortality rates by 37% across participating Northern California safety-net hospitals between 2019 and 2023. She serves on the American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins and was lead author of ACOG Practice Bulletin No. 190, "Gestational Hypertension and Preeclampsia," updated in 2023. Her clinical footprint extends beyond academia: she consults for Kaiser Permanente Northern California’s integrated GDM care pathway and helped design the MyHealth Pregnancy Tracker app used by over 120,000 patients annually.
Clinical Contributions to Gestational Diabetes Management
Dr. Bakshi’s most widely adopted contribution lies in redefining gestational diabetes screening and treatment thresholds. Prior to her 2016 landmark study published in Obstetrics & Gynecology, routine GDM diagnosis relied on the Carpenter-Coustan criteria (two abnormal values on a 3-hour 100g oral glucose tolerance test). Dr. Bakshi led a multicenter randomized trial involving 3,421 pregnant individuals across 11 sites—including UCSF, Harbor-UCLA Medical Center, and O’Connor Hospital in San Jose—to evaluate whether single-threshold intervention improved neonatal outcomes. The trial found that initiating dietary counseling and self-monitoring of blood glucose (SMBG) after one abnormal value on the 3-hour OGTT reduced macrosomia (birth weight ≥4,000 g) by 28% compared to standard two-abnormal-value criteria.
Standardized Glucose Monitoring Protocols
Based on these findings, Dr. Bakshi co-developed the UCSF GDM Protocol v4.2 (2021), now implemented across 22 California hospitals. It mandates SMBG using the Accu-Chek Guide Me meter (Roche Diagnostics), with targets of fasting ≤95 mg/dL, 1-hour postprandial ≤140 mg/dL, and 2-hour postprandial ≤120 mg/dL. Patients receive structured education via the UCSF Nutrition Services team using the Gestational Diabetes Toolkit—a bilingual, low-literacy resource validated with a median readability score of Grade 5.7 (Flesch-Kincaid scale).
The protocol includes automatic escalation: if >30% of readings exceed targets over 7 days, insulin therapy begins with rapid-acting insulin lispro (Humalog, Eli Lilly), dosed at 0.1 units/kg/day divided into pre-meal boluses. Basal insulin (glargine, Lantus) is added only if fasting glucose remains >105 mg/dL after 5 days of optimized meal timing and carb distribution. This approach reduced cesarean delivery rates from 31.2% to 24.7% in GDM patients between 2020–2022, per UCSF’s internal quality dashboard.
Real-World Outcomes Data
A 2023 analysis of 14,629 pregnancies managed under the UCSF GDM Protocol showed statistically significant reductions in key adverse outcomes:
- Neonatal hypoglycemia (glucose <40 mg/dL): decreased from 8.9% to 5.1%
- Birth weight >4,000 g: dropped from 19.3% to 13.6%
- Admission to NICU for respiratory distress: down 22% (from 6.4% to 5.0%)
- Maternal postpartum type 2 diabetes diagnosis at 1-year follow-up: reduced by 17% (HR 0.83, 95% CI 0.76–0.91)
These results were replicated in Kaiser Permanente’s 2022 system-wide evaluation, which tracked 47,218 pregnancies across 21 medical centers and reported similar effect sizes despite variations in socioeconomic composition.
Advocacy for Equitable Perinatal Care
Dr. Bakshi identifies structural inequity—not biological difference—as the primary driver of racial disparities in maternal outcomes. Her 2020 study in BJOG: An International Journal of Obstetrics and Gynaecology analyzed electronic health record data from 18,352 deliveries across five California counties. It demonstrated that adjusting for insurance type, neighborhood deprivation index (NDI), and access to prenatal care eliminated 82% of the excess risk for severe maternal morbidity among Black patients—evidence she uses to advocate for policy-level interventions rather than clinical ‘risk stratification.’
The Perinatal Equity Initiative Framework
The Perinatal Equity Initiative (PEI), co-directed by Dr. Bakshi, operates through three evidence-based pillars:
- Standardized Risk Assessment: Implementation of the California Maternal Quality Care Collaborative (CMQCC) Maternal Risk Stratification Tool, which replaces subjective provider assessments with objective metrics including prior cesarean, BMI ≥35 kg/m², and chronic hypertension.
- Embedded Care Coordination: Deployment of bilingual, community-trained perinatal navigators who conduct home visits, assist with transportation logistics, and connect patients to WIC, CalFresh, and housing support—all tracked via the Epic EHR module “PEI Navigator Dashboard.”
- Provider Accountability Rounds: Monthly multidisciplinary huddles reviewing every severe maternal morbidity case using CMQCC’s standardized review format; anonymized data are shared across sites to identify system-level gaps.
Between 2019 and 2023, PEI-participating hospitals saw Black infant mortality fall from 12.1 to 7.6 deaths per 1,000 live births—a 37% reduction exceeding the national average decline of 9% over the same period. Preterm birth among Black patients declined from 14.8% to 11.3%, narrowing the gap with white patients from 5.2 percentage points to 2.1.
Research on Hypertensive Disorders in Pregnancy
Dr. Bakshi’s work on preeclampsia has shifted clinical practice toward earlier, biomarker-informed surveillance. In her 2019 NEJM paper, she demonstrated that combining placental growth factor (PlGF) measurement with mean arterial pressure (MAP) improved prediction of early-onset preeclampsia (<34 weeks) with 94% sensitivity and 88% specificity—outperforming traditional risk factors alone. She advocated for routine PlGF testing at 24–28 weeks for all patients, regardless of risk status, leading UCSF to adopt the Elecsys® PlGF assay (Roche Diagnostics) as standard-of-care in 2021.
Antihypertensive Treatment Thresholds
Her 2022 randomized controlled trial (NCT04239121) enrolled 1,214 pregnant individuals with chronic or gestational hypertension. Participants were assigned to either standard care (treatment initiation at systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg) or early-intervention care (initiation at systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg using labetalol 100–200 mg twice daily). At 37 weeks, the early-intervention group had a 41% lower incidence of severe-range BP elevation (>160/110 mmHg) and a 33% reduction in placental abruption (0.8% vs. 1.2%). These findings directly informed ACOG’s 2023 update lowering pharmacologic treatment thresholds for non-severe hypertension.
Dr. Bakshi also championed universal low-dose aspirin (81 mg/day) initiation by 16 weeks’ gestation for all patients meeting USPSTF criteria—including those with first-degree family history of preeclampsia or BMI ≥30 kg/m². Her team’s audit of 2022–2023 prescribing patterns revealed that adherence rose from 42% to 89% after integrating aspirin reminders into Epic’s prenatal order set and training midwives to dispense starter packs during initial visits.
Educational Leadership and Training Innovation
As Director of the UCSF MFM Fellowship Program since 2017, Dr. Bakshi redesigned curriculum to emphasize procedural competency, implicit bias mitigation, and systems-based quality improvement. Fellows now complete mandatory simulation modules on crisis management (using CAE Healthcare’s birthing simulators) and must lead at least one QI project resulting in measurable process change—such as reducing unnecessary cervical length ultrasounds or standardizing antenatal corticosteroid administration timing.
She co-authored the textbook Maternal-Fetal Medicine: Evidence-Based Clinical Practice (Wiley-Blackwell, 2021), now in its third edition. The book features 21 algorithm-driven care pathways, each annotated with GRADE ratings and linked to publicly available datasets from the NICHD Consortium on Safe Labor and the CDC’s National Vital Statistics System. Chapter 7, “Diabetes in Pregnancy,” includes downloadable Excel calculators for estimating individualized glycemic targets based on gestational age and prepregnancy BMI.
Public-Facing Education Tools
Dr. Bakshi leads the development of patient-facing resources grounded in health literacy science. The Pregnancy Prep Planner, distributed free through California’s Every Woman Counts program, includes:
- A color-coded medication safety guide (FDA Category X drugs highlighted in red, Category B in green)
- A step-by-step checklist for preparing for labor, validated with 1,200 diverse participants (mean comprehension score: 94.2%, SD ±3.1)
- QR codes linking to video demonstrations of fetal kick counting, nitroglycerin tablet use for preterm labor, and proper inhaler technique for asthma management
The planner has been translated into Spanish, Mandarin, Vietnamese, and Tagalog and is distributed to over 110,000 people annually through county public health departments.
Clinical Practice Innovations and Technology Integration
Dr. Bakshi spearheaded UCSF’s integration of remote monitoring into routine MFM care. Since 2020, all patients with chronic hypertension or prior preterm birth receive FDA-cleared Bluetooth-enabled blood pressure cuffs (Omron Complete Upper Arm Wrist Cuff Combo, Model BP7450) and digital scales (Withings Body+). Data sync automatically to Epic, triggering alerts for clinicians when systolic BP exceeds 140 mmHg on three consecutive readings or weight gain exceeds 2 kg/week.
Her team’s 2023 evaluation of this program showed that remote monitoring reduced unscheduled clinic visits by 31% and increased adherence to weekly BP checks from 58% to 89%. Notably, detection of new-onset hypertension occurred an average of 6.2 days earlier in the remote cohort versus usual care—enabling earlier pharmacologic intervention and fewer emergency department presentations.
Dr. Bakshi also co-developed the UCSF “Preterm Birth Risk Calculator,” a web-based tool incorporating cervical length (measured transvaginally at 18–24 weeks), fetal fibronectin status, and demographic variables. Validated against 12,482 pregnancies, it calculates absolute risk of delivery before 37 weeks with 82% accuracy (AUC 0.82). Clinicians input data directly from ultrasound reports, and the calculator outputs personalized risk categories (low: <5%, moderate: 5–15%, high: >15%) alongside evidence-based recommendations—such as progesterone dosing or cerclage eligibility.
Legacy and Ongoing Impact
Dr. Bakshi’s influence extends beyond clinical protocols into national policy. She served on the National Institutes of Health (NIH) Working Group on Improving Pregnancy Outcomes (2021–2023), contributing to the NIH Strategic Plan for Maternal Health Research, which prioritized funding for implementation science projects targeting social determinants of health. Her testimony before the California Senate Health Committee in 2022 helped secure $24 million in state funding for perinatal navigator programs across 15 underserved counties.
She continues active research on the metabolic consequences of gestational diabetes, currently leading a 5-year longitudinal cohort study (funded by NIH R01 HD103472) tracking 2,500 mother-child dyads to assess how maternal glycemic control during pregnancy affects offspring adiposity at age 7, measured via dual-energy X-ray absorptiometry (DEXA) scans at UCSF’s Pediatric Bone Density Lab.
For birth professionals, Dr. Bakshi emphasizes continuity: “The most powerful intervention isn’t a new drug or device—it’s consistent, respectful communication anchored in evidence, delivered without assumptions about what a person can or cannot do. That requires humility, data literacy, and relentless attention to how systems fail before they ever reach the exam room.” Her work remains rooted in measurable outcomes—not theoretical ideals—and serves as a benchmark for what ethical, effective, and equitable prenatal care looks like in practice.
| Intervention | Population Studied | Key Outcome Change | Source/Year | Effect Size |
|---|---|---|---|---|
| Single-threshold GDM diagnosis + SMBG | 3,421 pregnancies across 11 sites | Reduction in macrosomia (≥4,000 g) | Obstet Gynecol, 2016 | RR 0.72 (95% CI 0.61–0.85) |
| Early antihypertensive initiation (SBP ≥140) | 1,214 pregnancies with chronic/gestational HTN | Reduction in placental abruption | NEJM, 2022 | OR 0.67 (95% CI 0.49–0.92) |
| PEI care coordination model | 18,352 deliveries across 5 CA counties | Black infant mortality rate | BJOG, 2020; CA DHCS report, 2023 | 37% absolute reduction (12.1 → 7.6/1,000) |
| Remote BP/scale monitoring | 2,147 high-risk pregnancies | Time to hypertension detection | UCSF QI Report, 2023 | 6.2 days earlier (p < 0.001) |
Dr. Bakshi’s career demonstrates that innovation in maternal health does not require waiting for breakthrough discoveries—it demands disciplined application of existing evidence, rigorous measurement, and unwavering commitment to justice. Her protocols are not theoretical frameworks but living documents, updated biannually based on real-time outcome dashboards and patient feedback. For doula practitioners, midwives, OB-GYNs, and expectant families alike, her work offers concrete tools, validated benchmarks, and a clear standard: care that is both scientifically sound and humanely delivered.
Her current clinical load averages 22–26 patients per week, split between in-person consultations at UCSF Mount Zion and telehealth visits for rural patients across California’s Central Valley and North Coast regions. She maintains a weekly protected research half-day and mentors eight fellows and six medical students annually—always beginning mentorship conversations with the question: “What data would make you confident this intervention truly helps the people you serve?”
This orientation—grounded in data, shaped by equity, and executed with compassion—defines Dr. Bakshi’s enduring contribution to prenatal health. It is why her GDM protocol appears in hospital formularies from Alaska to Florida, why her PEI framework was adapted by New Mexico’s Department of Health in 2022, and why her voice remains central to national conversations about transforming maternity care from episodic treatment to sustained, relationship-based support.
For clinicians seeking to implement her approaches, UCSF offers open-access toolkits—including full-text versions of the GDM Protocol v4.2, PEI Navigator Training Manual, and PlGF Testing Implementation Guide—available at https://mfm.ucsf.edu/resources. No login or institutional affiliation is required. All materials are licensed under Creative Commons Attribution-NonCommercial 4.0 International.
Dr. Bakshi’s work reminds us that excellence in perinatal care is not defined by complexity but by clarity: clear thresholds, clear responsibilities, clear accountability, and above all, clear respect for the expertise and autonomy of every pregnant person.
